českyenglish

General partners

Pfizer_(2021)_300px_bez_okraje.png

Chiesi-logo_web.png

VIEW AN ABSTRACT

METFORMIN TREATMENT IS ASSOCIATED WITH IMPROVED QUALITY OF LIFE AND OUTCOME IN PATIENTS WITH DIABETES AND ADVANCED HEART FAILURE (HFREF)
Topic: field
Type: Presentation - doctors , Number in the programme: 17
Beneš J.1, Kotrč M.1, Kroupová K.1, Wohlfahrt P.2, Kovář J.3, Franeková J.4, Hošková L.1, Pelikánová T.5, Kautzner J.1, Melenovský V.1

1 Klinika kardiologie, IKEM, Praha, 2 Centrum kardiovaskulární prevence, Thomayerova nemocnice, Praha, 3 Centrum experimentální medicíny, IKEM, Praha, 4 Pracoviště laboratorních metod, IKEM, Praha, 5 Klinika diabetologie, IKEM, Praha


Background: The role of metformin (MET) in the treatment of patients with advanced HFrEF and type 2 diabetes mellitus (DM) is not firmly established. We studied the impact of MET on metabolic profile, quality of life (QoL) and survival in these patients.
Methods: A total of 847 stable patients with advanced HFrEF (57.4± 11.3 years, 67.7% NYHA III/IV, LVEF 23.6± 5.8%) underwent clinical and laboratory evaluation and were prospectively followed for a median of 1126 (IQRs 410; 1781) days for occurrence of death, urgent heart transplantation or mechanical circulatory support implantation.
Results: A subgroup of 380 patients (44.9%) had DM, 87 of DM patients (22.9%) were treated with MET. Despite worse insulin sensitivity and more severe DM (higher BMI, HbA1c, worse insulin resistance), MET-treated patients exhibited more stable HF marked by lower BNP level (400 vs. 642 ng/L), better LV and RV function, lower mitral and tricuspid regurgitation severity, were using smaller doses of diuretics (all p< 0.05). Further, they had higher eGFR (69.23 vs. 63.34 ml/min/1.73m2) and better QoL (MLHFQ: 36 vs. 48 points, p= 0.002).
Compared to diabetics treated with other glucose-lowering agents, MET-treated patients had better event-free survival even after adjustment for BNP, BMI and eGFR (p= 0.035). Propensity score-matched analysis with 17 covariates yielded 81 pairs of patients and showed a significantly better survival for MET-treated subgroup (p= 0.01, Fig. 1).
Conclusion: MET treatment in patients with advanced HFrEF and DM is associated with improved outcome by mechanisms beyond the improvement of blood glucose control.